Please note: This post is not intended for distribution or publication, directly or indirectly, to US persons or in or into the United States, any EEA member state, Australia, Canada, the Republic of South Africa or Japan or any other jurisdiction where it is unlawful to distribute this post.
You will hopefully have seen our post on Wednesday announcing the publication of the Prospectus and website for our Conviction Life Sciences Company IPO.
Many of you have been kind enough to contact us to express interest and ask if the company will be available with your specific stockbroker.
On that point - we are now in the process of getting the various investment platform companies and stockbrokers set up to make the company as widely available as possible.
To help us in that endeavour, if you are interested in investing, we would be extremely grateful if you might be willing to take a moment to fill in a online survey to let us know your level of interest and where your investment funds sit.
As a reminder, this could be in pension, ISA or general investment & trading accounts - it’s entirely up to you.
The results of this survey will help us ensure that as many of the investment platforms and stockbroking firms as possible will do the admin' required to make the company available to you for investment.
Please be assured that any information you provide will be treated in the strictest confidence. We will not pass any of your personal details on to the investment platforms.
We have designed the survey to be incredibly easy to use and to ask as few questions as possible. It should take no longer than one or two minutes for you to complete.
We will update you further next week as things develop.
Andrew Craig is a director of Plain English Finance Limited ("Plain English Finance") which is authorised and regulated by the Financial Conduct Authority (564876) with its registered office at Stag Gates House, 63/64 The Avenue, Southampton, Hampshire SO17 1XS, United Kingdom and this document is being issued by Plain English Finance. Certain elements of this post, most particularly, the references to the Conviction Life Sciences Company (the "Company") can be considered a financial promotion.
This is intended for UK residents only.
This post, which has been issued by Plain English Finance, is a financial promotion and is not intended to be investment advice. This post is intended for UK residents only.
The purpose of this post is to provide summary information regarding the Company and is for information and discussion purposes only; it should not be considered an offer or solicitation of an offer to buy or sell shares in the capital of the Company. In particular, this post does not constitute an offer to sell, or the solicitation of an offer to acquire or subscribe for shares in the capital of the Company in any jurisdiction where to do so would be unlawful.
This post is an advertisement and does not constitute a prospectus or an offer in respect of any securities and is not intended to provide the basis for any decision in respect of the Company. An investment decision must be made solely on the basis of the prospectus issued by the Company (especially the risk factors set out therein) and which is available on the Company’s website at www.clsc.uk, subject to certain access restrictions.
Plain English Finance does not make any recommendations regarding the suitability of any product for you and the information provided here should not be considered as investment or other advice or a recommendation to buy, sell or hold a particular investment.
To reiterate, investments mentioned herein may not be suitable for you and you must make your own independent assessment and rely on your own judgement (or that of your financial adviser) in order to determine whether any particular investment represents a suitable investment opportunity for you on the basis of your personal circumstances, tax position and available financial resources and the legal, regulatory, tax and investment consequences and risks of investing. If you are in any doubt about the information here or on our or the Company's websites please consult your financial or other professional adviser.
The Company operates under the Companies (Guernsey) Law 2008, as amended, and is not regulated as a collective investment scheme by the Financial Conduct Authority of the United Kingdom. Your capital is at risk with this investment. The value of shares and a return from them is not guaranteed and the share price can fall as well as rise due to stock market movements. When you sell your investment you may get back less than you originally invested. The price of shares in the Company is determined by market supply and demand and may be different to the net asset value of the Company.
Past performance is not a reliable indicator of future results. Forecasts are not a reliable indicator of future performance. Investments in the Company are subject to risks associated with investments in the biotechnology sector. This post may include statements that are, or may be deemed to be, "forward-looking statements". Forward-looking statements are subject to risks and uncertainties and, accordingly, the Company’s actual future financial results and operational performance may differ materially from the results and performance expressed in, or implied by, the statements. These forward-looking statements speak only as at the date of this post and cannot be relied upon as a guide to future performance.
The Ordinary Shares have not been and will not be registered under the United States Securities Act of 1933 (as amended) (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered or sold within the United States or to, or for the account or benefit of, US Persons (as defined in Regulation S under the US Securities Act ("Regulation S")), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction in the United States. In addition, the Company has not been and will not be registered under the United States Investment Company Act of 1940, (as amended) (the "US Investment Company Act"), and recipients of the Prospectus will not be entitled to the benefits of that Act.
This post is not for publication or distribution, directly or indirectly, in or into the United States of America. This post is not an offer of securities for sale into the United States. No public offering of securities is being made in the United States.
The offer and sale of Ordinary Shares has not been and will not be registered under the applicable securities laws of any member state of the EEA, Canada, Japan or the Republic of South Africa. Subject to certain exemptions, the Ordinary Shares may not be offered to or sold within any member state of the EEA, Canada, Japan or the Republic of South Africa or to any national, resident or citizen of any member state of the EEA, Canada, Japan or the Republic of South Africa.